DDL-218

DDL-218 is a novel, orally brain-permeable small molecule that acts as a transcription factor modulator to enhance sirtuin 1 (SirT1) expression by targeting the apolipoprotein E4 (ApoE4) pathway. Designed for potential disease modification in Alzheimer’s disease, particularly in ApoE4-expressing individuals, DDL-218 promotes SirT1 mRNA and protein levels in neuronal cells and Alzheimer’s disease mouse models, resulting in improvements in memory and cognitive function. Mechanistically, it increases the transcription factor NFYb and upregulates PRMT5, which displaces ApoE4 from the SirT1 gene promoter, thereby restoring SirT1 transcription. Beyond SirT1, DDL-218 alters the expression of proteins involved in neurotransmitter release, synaptic plasticity, and mitochondrial function. In preclinical studies, 56-day oral administration of DDL-218 produced significant neuroprotective effects without observable adverse reactions. The drug is positioned as a potential complement to current amyloid-targeted therapies and may address pathology-related alterations that these therapies do not[1][3][5][6].